Instruction for reporting suspected unexpected serious adverse reactions (SUSARs) in the HOT-COVID trial

Patients in the intensive care unit experience numerous serious adverse events (SAEs). Selected SAEs will be reported through the daily registrations within the eCRF, these include acute myocardial ischaemia, acute ischaemic stroke, acute intestinal ischaemia and shock. When an ischaemic SAE is registered, the physician in charge is asked whether the event is related, possibly related, or not related to oxygen. The sponsor (or delegated party) will then assess the relationship with oxygen and evaluate whether an adverse reaction (AR) or a severe adverse reaction (SAR) is present. No other routine reporting of SARs will be conducted in the HOT-COVID trial.

SUSARs however, will have to be registered and reported as described below:

A SUSAR is defined as an SAE, which is suspected to be related directly to oxygen supplementation and is unexpected, that is, if it is not consistent with expected ARs related to oxygen supplementation (e.g. ARDS and atelectasis).

**Suspected unexpected serious adverse reactions (SUSARs) have to be reported immediately**

Phone: **+45 21 18 25 43**

**Complete the SUSAR form in the site master file #14 (can be found at** [**www.cric.nu/hot-covid**](http://www.cric.nu/hot-covid)**) and send it by email to the coordinating center within 24 hours from registration of the SUSAR**

e-mail: **hot-covid@cric.nu**

**You will receive an email from the coordinating center when the report has been registered**

**A standard operating procedure (SOP) for reporting of SUSARs to sponsor can be found in the site master file #14 (at** [**www.cric.nu/hot-covid**](http://www.cric.nu/hot-covid)**)**

The local principal investigator is responsible for determining the causal relationship of a SUSAR as either possibly, probably or definitively related to oxygen supplementation.

Final evaluation of whether an event is considered to be a SUSAR is conducted by the sponsor, all SUSARs will be reported the relevant authorities within seven days (by sponsor).

If an adverse reaction is considered to be a SUSAR and the situation allows it, please call the coordinating center before withdrawing the patient from the trial:

* Call the HOT-COVID hotline (+45 21 18 25 43).

SARs and SUSARs will be monitored by the data safety and monitoring committee on a regular basis according to the protocol.

All SUSARs will be registered in the EudraVigilance database. Investigators at all participating sites will receive information by email if a SUSAR is reported and a yearly report of all registered SARs.

**National principal investigators, please report SUSARs to your Ethics Committee as per local requirements**

* **Copies of any reporting and correspondence to and from your local ethic committee should be sent to the coordinating centre by email**